Trial Profile
A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Focal segmental glomerulosclerosis; Lipoid nephrosis; Nephrotic syndrome
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 16 Dec 2019 Planned End Date changed from 29 Jun 2020 to 30 Jun 2020.
- 16 Dec 2019 Planned primary completion date changed from 11 Dec 2019 to 30 May 2020.